The Pacific Northwest is a hotbed for innovation, and the potential for growth in the near future is enormous. Forward-thinking scientists, entrepreneurs, academics and government leaders are gathering in progressive cities like Seattle, where medical innovation and scientific discovery play an increasingly important role in the economy and our nation's health.
Medical innovation has traditionally been a cornerstone of a flourishing America, especially in Washington state. Besides keeping us healthy, the U.S. health-care industry provides good jobs: approximately 14 million jobs today and an expected 3 million new jobs between 2006 and 2016 — more than any other industry — according to the Bureau of Labor Statistics.
America is still the world leader in medical innovation, but that role cannot be taken for granted. We are losing our edge as other countries are joining the race. Europe is now pulling ahead of the U.S. in production of new chemical entities. Asian countries outpace the U.S. in research and development spending. An increased demand for skilled science and engineering students in Europe, China and India has resulted in a reverse brain-drain, with many of our skilled immigrant workers leaving the U.S. to work abroad.
From Singapore to Sweden, other nations are investing in innovation and making it an economic priority. If the United States wants to compete in the new global economy, we will have to do the same.
Washington state boasts leading biotechnology companies, top medical-research universities, and a community of venture capitalists and government officials who embrace and support the growth of life sciences. The biopharmaceutical industry in Washington employed nearly 20,000 people in 2006, paying $1.6 billion in wages, an average wage of $81,499.
In the last month alone, Seattle pharmaceutical company Trubion announced a private partnership to develop a new treatment for leukemia; researchers at the University of Washington found a new way to identify gene links and candidates for diseases like cystic fibrosis or sickle cell anemia more efficiently; and Seattle biotechnology company Amgen announced its cancer drug Vectibix met treatment goals in a late-stage study focusing on patients with colon cancer. Medical innovation is certainly thriving here.
With policies that support its continued growth, Washington could become a global leader in medical innovation in the near future. On Monday and Tuesday, the Best and Brightest Forum on Medical Innovation and the Governor's Life Sciences Summit — both taking place in Seattle — will initiate important conversations about the local impact and growth potential of medical innovation, and what can be done to preserve and protect this critical element of the region's economy.
In President Obama's words, we must "once again put science at the top" in our budgets and in our legislation. That includes creating incentives to encourage collaborative research across the public and private sectors — not a given in this economy.
At the federal level, policies must also be modernized to increase incentives for investment in research and its application, increase federal budgets for the life sciences, improve science, technology, engineering and math (STEM) education, and attract and retain the best and brightest minds from this country and around the world. These changes are imperative to ensuring future advances and breakthroughs in the life science and medicine in America.
The real key to economic recovery is discovery. We must keep the wheels of innovation greased by establishing and maintaining policies that nurture scientific research, medical discovery and its application. Finding cures for cancer and other life-threatening illnesses, and creating new and better treatments for chronic diseases, are not only important to our health, but will also help us build a vibrant economy once again.
Richard A. Gephardt is former Democratic majority leader of the U.S. House of Representatives and the chairman of the Council for American Medical Innovation.
Breaux and Gephardt. Gerard and Maloney. Berman and Podesta. According to First Street, these were among the most powerful lobbyists in Washington this year.
...Tom O'Donnell, Gephardt Government Affairs Group. O'Donnell and his former Capitol Hill boss, ex-House Democratic Leader Richard Gephardt (Mo.), have done well since joining forces...
Read More
Gephardt's former chief of staff Tom O'Donnell talks to National Journal about post-debt ceiling debate prospects for bipartisanship.
Read More
Video: How Will FAA Crisis Affect You?
Watch Video
Debt-limit votes have been called the "burden of the majority" — an unpleasant chore that needed to be done by whichever party happens to be in power.
Read More
Christina Hamilton, Former Chief of Staff to House Appropriations Committee Chairman Dave Obey, will join the firm. As a Senior Vice President with the firm, Christina will support the firm’s health, energy, transportation, trade and appropriations clients.
Watch Video
Life on the outside after more than 41 years in Congress hasn’t been much different for former House Appropriations Chairman David Obey, D-Wis. — or so it seems.
Read More
Dick Gephardt participated in Vice President Joe Biden, Dr. Jill Biden and Secretary of State Hillary Clinton’s welcoming lunch honoring Her Excellency Dr. Angela Merkel, Chancellor of the Federal Republic of Germany.
Watch Video
Gephardt Government Affairs President & CEO Dick Gephardt announced that Former House Appropriations Committee Chairman Dave Obey will join the firm.
Read More
"If there was a tough leadership assignment in the country right now, it would be this job — at the top of everybody's list," says former House majority leader Richard Gephardt, who first recommended Panetta to President Clinton as his budget director. Panetta later became White House chief of staff.
Read More
Dick comments on the "Gephardt rule" as the debt ceiling debate heats up.
Read More